Authors: BAKKER M DROZ JP HANAUSKE AR VERWEIJ J VANOOSTEROM AT GROEN HJM PACCIARINI MA DOMENIGONI L VANWEISSENBRUCH F PIANEZZOLA E DEVRIES EGE

Citation: M. Bakker et al., BROAD PHASE-II AND PHARMACOKINETIC STUDY OF METHOXY-MORPHOLINO DOXORUBICIN (FCE 23762-MMRDX) IN NON-SMALL-CELL LUNG-CANCER, RENAL-CANCER AND OTHER SOLID TUMOR PATIENTS, British Journal of Cancer, 77(1), 1998, pp. 139-146

Authors: DETAKATS PG DUNLOP D KAYE SB FYFE DW BAKER P PACCIARINI MA VALOTA O KERR DJ

Citation: Pg. Detakats et al., PHASE IB STUDY OF METHOXYMORPHOLINODOXORUBICIN (PNU-152243 FCE-23762)ADMINISTERED IN A 3 OR 4 WEEKLY SCHEDULE, European journal of cancer, 33, 1997, pp. 1133-1133

Authors: PERSIANI S ROCCHETTI M PACCIARINI MA HOLT B TOON S STROLINBENEDETTI M

Citation: S. Persiani et al., THE EFFECT OF FOOD ON CABERGOLINE PHARMACOKINETICS AND TOLERABILITY IN HEALTHY-VOLUNTEERS, Biopharmaceutics & drug disposition, 17(5), 1996, pp. 443-455

Authors: ANDREOTTI AC PIANEZZOLA E PERSIANI S PACCIARINI MA BENEDETTI MS PONTIROLI AE

Citation: Ac. Andreotti et al., PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF CABERGOLINE, A PROLACTIN-LOWERING DRUG, AFTER ADMINISTRATION OF INCREASING ORAL DOSES (0.5, 1.0, AND 1.5 MILLIGRAMS) IN HEALTHY MALE-VOLUNTEERS, The Journal of clinical endocrinology and metabolism, 80(3), 1995, pp. 841-845

Authors: VASEY PA BISSETT D STROLINBENEDETTI M POGGESI I BREDA M ADAMS L WILSON P PACCIARINI MA KAYE SB CASSIDY J

Citation: Pa. Vasey et al., PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF 3'-DEAMINO-3'-(2-METHOXY-4-MORPHOLINYL)DOXORUBICIN (FCE-23762), Cancer research, 55(10), 1995, pp. 2090-2096